莱斯康制药 LXRX 深 沪
已收盘 07-02 16:00:00 美东时间
2.32
-0.020
-0.85%
华盛通- 最 高2.44
- 今 开2.35
- 成交量 263.00万股
- 最 低 2.27
- 昨 收 2.34
- 总市值 103.05万
- 52周最高 2.68
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 1.00
- 委 比 -66.75%
- 总股本 0.00亿
- 历史最高 19.62
- 量 比 0.24
- 振 幅 7.26%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals LXRX 暴涨9.6% 借生物科技板块涨势触及五十二周高点
莱克西肯制药（LXRX）当日大涨9.6%，收盘接近2.53美元的52周高点，开盘价2.28美元，日内最高触及2.51美元，当日成交量1321613股，换手率0...
06-26 22:42
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX
JR Research sees Amazon (AMZN) as a compelling opportunity, citing its massive $464 billion backlog and dominant position in the AI compute boom. Super Micro Computer (SMCI) also receives a more favor...
05-28 01:05
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.
05-11 23:10
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals has secured a $100 million loan facility from Hercules Capital to enhance financial flexibility and support upcoming milestones. The initial $55 million will repay an existing loan, with additional tranches available upon achieving specific milestones. The facility features an 18-month interest-only period and a floating rate of prime plus 3.1%, maturing in 2030. Lexicon's CFO highlighted the deal's benefits for accessing ...
05-04 20:05
Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg
04-17 20:02
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
03-30 20:04
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide
03-23 19:38
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851, developed by Novo Nordisk and licensed from Lexicon Pharmaceuticals, is a first-in-class oral non-incretin candidate for obesity and metabolic disorders. Novo Nordisk has initiated a Phase 1 study, and Lexicon has received a second $10 million milestone payment, with potential total payments up to $1 billion plus royalties. Trials in 96 participants are evaluating safety, tolerability, and efficacy. LX9851 inhibits ACSL5 and activates the...
03-23 11:30
